Advertisement

Immuno-Oncology in the Era of Personalized Medicine

  • William R. GwinIII
  • Mary L. Disis
  • Erika Ruiz-GarciaEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1168)

Abstract

Personalized medicine in oncology utilizes evidence derived from genetic, immune, and proteomic profiling to inform therapeutic options as well as provide prognostic information for each unique individual and their tumor. Our ability to biologically and immunologically define each patient’s tumor has been driven by the development of assays characterizing the genomic and proteomic profiles of tumors that in turn have led to the development of large biologic databases and computational tools for the analysis of these large data sets. In Immuno-oncology, the introduction of checkpoint inhibitors and their approval across multiple tumor types has led to the recognition that the majority of patients will not clinically respond to these therapies but will remain at risk for the development of significant immunologic side effects. This challenge highlights the need for the development and validation of both predictive biomarkers for response to such therapies as well as biomarkers prognostic of disease course. Despite extensive investigation into predictive biomarkers using these biologic databases and computational methods, only recently has progress been made in this area. This progress is the first step allowing us to identify patients likely to benefit from these therapies and moving our field closer to a truly personalized approach to the use of immune therapies in oncology.

Keywords

Immune monitoring T-cell Antibody Immunologic biomarkers Predictive biomarkers Prognostic biomarkers 

Notes

Acknowledgements

MLD was supported by NCI grant (U01 CA154967), a Komen Leadership Grant, an American Cancer Society Clinical Research Professorship, and the Athena Distinguished Professorship for Breast Cancer Research.

Conflict of Interest

MLD is a stockholder in Epithany and receives grant support from Celgene, EMD Serono, Epithany and Janssen.

References

  1. 1.
    Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372:793–795CrossRefGoogle Scholar
  2. 2.
    Klapper JA et al (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293–301CrossRefGoogle Scholar
  3. 3.
    Smith FO et al (2008) Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14:5610–5618CrossRefGoogle Scholar
  4. 4.
    Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med 375:1823–1833CrossRefGoogle Scholar
  5. 5.
    Le DT et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY) 357:409–413CrossRefGoogle Scholar
  6. 6.
    Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28:4531–4538CrossRefGoogle Scholar
  7. 7.
    Linsley PS, Speake C, Whalen E, Chaussabel D (2014) Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLoS One 9:e109760CrossRefGoogle Scholar
  8. 8.
    Callari M et al (2014) Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. Mol Oncol 8:1278–1289CrossRefGoogle Scholar
  9. 9.
    Duarte CW et al (2012) Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One 7:e29653CrossRefGoogle Scholar
  10. 10.
    Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY) 313:1960–1964CrossRefGoogle Scholar
  11. 11.
    Pages F et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666CrossRefGoogle Scholar
  12. 12.
    Jerome Galon BM, Marliot F, Ou F-S, Bifulco CB (2016) Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. J Clin Oncol 34(suppl):3500CrossRefGoogle Scholar
  13. 13.
    Adams S et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959–2966CrossRefGoogle Scholar
  14. 14.
    Donnem T et al (2015) Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung Cancer. Clin Cancer Res 21:2635–2643CrossRefGoogle Scholar
  15. 15.
    Tumeh PC et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571CrossRefGoogle Scholar
  16. 16.
    Disis ML et al (2014) HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother 63:101–109CrossRefGoogle Scholar
  17. 17.
    Ren J et al (2017) Adaptive T cell responses induced by oncolytic herpes simplex virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. Oncoimmunology 6:e1264563CrossRefGoogle Scholar
  18. 18.
    Bolen CR et al (2017) Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv 1:1884–1890CrossRefGoogle Scholar
  19. 19.
    Westin JR et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69–77CrossRefGoogle Scholar
  20. 20.
    Socinski MA et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301CrossRefGoogle Scholar
  21. 21.
    Herbst RS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567CrossRefGoogle Scholar
  22. 22.
    Ansell SM et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319CrossRefGoogle Scholar
  23. 23.
    Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science (New York, NY) 348:69–74CrossRefGoogle Scholar
  24. 24.
    Alexandrov LB et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421CrossRefGoogle Scholar
  25. 25.
    Linnemann C et al (2015) High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 21:81–85CrossRefGoogle Scholar
  26. 26.
    Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61CrossRefGoogle Scholar
  27. 27.
    Lu YC et al (2014) Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 20:3401–3410CrossRefGoogle Scholar
  28. 28.
    Cohen CJ et al (2015) Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125:3981–3991CrossRefGoogle Scholar
  29. 29.
    Stronen E et al (2016) Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science (New York, NY) 352:1337–1341CrossRefGoogle Scholar
  30. 30.
    Le DT et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520CrossRefGoogle Scholar
  31. 31.
    Challa-Malladi M et al (2011) Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20:728–740CrossRefGoogle Scholar
  32. 32.
    Sun T, Hu Z, Shen H, Lin D (2009) Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res 69:6011–6014CrossRefGoogle Scholar
  33. 33.
    Breunis WB et al (2008) Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother (Hagerstown, MD) 31:586–590CrossRefGoogle Scholar
  34. 34.
    Queirolo P et al (2013) Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study. Cancer Investig 31:336–345CrossRefGoogle Scholar
  35. 35.
    Gogas H et al (2010) Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med 8:108CrossRefGoogle Scholar
  36. 36.
    Pancoska P et al (2014) A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One 9:e86375CrossRefGoogle Scholar
  37. 37.
    Bedognetti D et al (2013) CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 109:2412–2423CrossRefGoogle Scholar
  38. 38.
    Lima L et al (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a southern Europe population. BJU Int 116:753–763CrossRefGoogle Scholar
  39. 39.
    Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD (2009) Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int 104:867–873CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • William R. GwinIII
    • 1
  • Mary L. Disis
    • 1
  • Erika Ruiz-Garcia
    • 2
    Email author
  1. 1.Cancer Vaccine InstituteUniversity of WashingtonSeattleUSA
  2. 2.Department of Gastrointestinal Medical Oncology & Translational Medicine LaboratoryInstituto Nacional de CancerologiaMexico CityMexico

Personalised recommendations